Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

ER-Positive HER2-Negative Breast Cancer

Interventions

DRUG: AZD9833
DRUG: AZD9833 Placebo
DRUG: Anastrozole
DRUG: Anastrozole placebo
DRUG: Letrozole
DRUG: Letrozole placebo
DRUG: Palbociclib
DRUG: Abemaciclib
DRUG: Luteinizing hormone-releasing hormone (LHRH) agonist
DRUG: Ribociclib

Sponsor

AstraZeneca